Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,370 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC.
Yoneshima Y, Morita S, Ando M, Nakamura A, Iwasawa S, Yoshioka H, Goto Y, Takeshita M, Harada T, Hirano K, Oguri T, Kondo M, Miura S, Hosomi Y, Kato T, Kubo T, Kishimoto J, Yamamoto N, Nakanishi Y, Okamoto I. Yoneshima Y, et al. Among authors: kondo m. J Thorac Oncol. 2021 Sep;16(9):1523-1532. doi: 10.1016/j.jtho.2021.03.027. Epub 2021 Apr 27. J Thorac Oncol. 2021. PMID: 33915251 Free article. Clinical Trial.
Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
Goto Y, Shinjo K, Kondo Y, Shen L, Toyota M, Suzuki H, Gao W, An B, Fujii M, Murakami H, Osada H, Taniguchi T, Usami N, Kondo M, Hasegawa Y, Shimokata K, Matsuo K, Hida T, Fujimoto N, Kishimoto T, Issa JP, Sekido Y. Goto Y, et al. Among authors: kondo m, kondo y. Cancer Res. 2009 Dec 1;69(23):9073-82. doi: 10.1158/0008-5472.CAN-09-1595. Epub 2009 Nov 3. Cancer Res. 2009. PMID: 19887624
Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study.
Ichikawa M, Suzuki R, Kataoka K, Noda Y, Shindoh J, Matsumoto S, Tanikawa Y, Suzuki K, Baba K, Shindo Y, Kondo M, Imaizumi K, Kume H, Hasegawa Y, Takagi K, Taniguchi H. Ichikawa M, et al. Among authors: kondo m. Lung Cancer. 2010 Sep;69(3):319-22. doi: 10.1016/j.lungcan.2009.11.021. Epub 2010 Jan 6. Lung Cancer. 2010. PMID: 20053476 Clinical Trial.
Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial.
Usami N, Yokoi K, Hasegawa Y, Taniguchi H, Shindo J, Yamamoto M, Suzuki R, Imaizumi K, Kondo M, Shimokata K; Central Japan Lung Study Group. Usami N, et al. Among authors: kondo m. Int J Clin Oncol. 2010 Dec;15(6):583-7. doi: 10.1007/s10147-010-0118-x. Epub 2010 Aug 17. Int J Clin Oncol. 2010. PMID: 20714770 Clinical Trial.
Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System.
Morise M, Taniguchi H, Saka H, Shindoh J, Suzuki R, Kojima E, Hase T, Ando M, Kondo M, Saito H, Hasegawa Y. Morise M, et al. Among authors: kondo m. Mol Clin Oncol. 2014 Nov;2(6):991-996. doi: 10.3892/mco.2014.354. Epub 2014 Jul 22. Mol Clin Oncol. 2014. PMID: 25279187 Free PMC article.
Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?
Kato T, Morise M, Ando M, Kojima E, Ogasawara T, Suzuki R, Shindoh J, Matsumoto M, Sugino Y, Ogawa M, Nozaki Y, Hase T, Kondo M, Saito H, Hasegawa Y. Kato T, et al. Among authors: kondo m. J Cancer Res Clin Oncol. 2016 Jul;142(7):1629-40. doi: 10.1007/s00432-016-2170-z. Epub 2016 May 11. J Cancer Res Clin Oncol. 2016. PMID: 27166967
4,370 results